| Literature DB >> 30046953 |
Lan Li1, Xuwen Qiao1, Jin Chen1, Yuanpeng Zhang1, Qisheng Zheng2, Jibo Hou3,4.
Abstract
Vaccine immunization is now one of the most effective ways to controlEntities:
Keywords: GEM particles; Griffithsin; Lactic acid bacteria; PRRSV; Purification
Mesh:
Substances:
Year: 2018 PMID: 30046953 PMCID: PMC7088258 DOI: 10.1007/s10295-018-2061-1
Source DB: PubMed Journal: J Ind Microbiol Biotechnol ISSN: 1367-5435 Impact factor: 3.346
Fig. 1Schematic representation illustrating the process of GEM particle displaying PRRSV by PA-GRFT
Fig. 2Analysis of PA-GRFT expression. a SDS-PAGE stained with Coomassie Brilliant Blue. b Western blotting analysis using the anti-His tag antibody. a, b Lane M, protein size markers; Lane 1, supernatant of E. coli BL21 pET32a-PA-GRFT after homogenization; Lane 2, sediment of E. coli BL21 pET32a-PA-GRFT after homogenization; Lane 3, supernatant of E. coli BL21 pET32a after homogenization; Lane 4, sediment of E. coli BL21 pET32a after homogenization
Fig. 3Binding of PA-GRFT to OVA-coated wells and detection by ELISA
Fig. 4SDS-PAGE analysis of binding efficiency of PA-GRFT to GEM particles. Lane M protein size markers; Lane 1 the crude PA-GRFT extract; Lane 2 negative control, the crude extract containing no PA-GRFT incubated with GEM particles; Lanes 3–8, PA-GRFT loaded onto GEM particles 25, 50, 100, 120, 150 and 180 μg of the crude PA-GRFT extract incubated with GEM particles, respectively
Fig. 5SDS-PAGE analysis of the reaction time between GEM particles and PA-GRFT. Lane M, protein size markers; Lanes 1–3 PA-GRFT loaded onto GEM particles, the crude PA-GRFT extract incubated with GEM particles for 1, 3 and 5 min, respectively
Fig. 6Analysis of the separation of PRRSV from cell culture onto the GEM particles. a Western blotting detection using anti-PRRSV GP5 protein monoclonal antibody. b SDS-PAGE analysis stained with Coomassie Brilliant Blue. Lane M, protein size markers; Lanes 1,10 virus stock; Lanes 2–5, supernatant corresponding to 30, 40, 50 and 60 mL of virus purification by the crude PA-GRFT extract; Lanes 6–9, PRRSV loaded onto GEM particles corresponding to 30, 40, 50 and 60 mL of virus purification by the crude PA-GRFT extract; Lane 11, supernatant corresponding to 30 mL of virus purification by the crude extract contains no PA-GRFT; Lane 12, PRRSV loaded onto GEM particles corresponding to 30 mL of virus purification by the crude extract containing no PA-GRFT; Lane 13, supernatant corresponding to 30 mL of virus purification incubated with GEM particles; Lane 14, PRRSV loaded onto GEM particles corresponding to 30 mL of virus purification incubated with GEM particles; Lane 15, the crude PA-GRFT extract
Fig. 7Detection of PRRSV on the surface of GEM particles by immunofluorescence microscopy. a PRRSV loaded onto GEM particles by the crude PA-GRFT extract. b PRRSV loaded onto GEM particles by the crude extract containing no PA-GRFT. c PRRSV loaded onto GEM particles incubated with GEM particles
Fig. 8Western blotting detection using swine PRRSV positive sera. Lane M, protein size markers; Lane 1, virus stock; Lane 2, supernatant corresponding to 50 mL of virus purification by the crude PA-GRFT extract; Lane 3, PRRSV loaded onto GEM particles corresponding to 50 mL of virus purification by the crude PA-GRFT extract; Lane 4, supernatant corresponding to 50 mL of virus purification by the crude extract containing no PA-GRFT; Lane 5, PRRSV loaded onto GEM particles corresponding to 50 mL of virus purification by the crude extract containing no PA-GRFT; Lane 6, supernatant corresponding to 50 mL of virus purification incubated with GEM particles; Lane 7, PRRSV loaded onto GEM particles corresponding to 50 mL of virus purification incubated with GEM particles; Lane 8, the non-infected MARC-145 cells
Fig. 9Determination of TCID50 of supernatant after virus purification and virus stock by an end-point dilution assay on MARC-145 cells. 1 virus stock, 2–5 supernatant corresponding to 30, 40, 50 and 60 mL of virus purification by the crude PA-GRFT extract; 6. supernatant corresponding to 30 mL of virus purification by the crude extract containing no PA-GRFT; 7 supernatant corresponding to 30 mL of virus purification incubated with GEM particles